Calidi Biotherapeutics will host a live investor webinar on April 24, 2025, at 4:15 p.m. ET, featuring its new Chief Medical Officer, Dr. Guy Travis Clifton. The event will provide critical insights into the company's developing cancer immunotherapy pipeline, focusing on its proprietary stem cell-based delivery platforms for oncolytic virus therapies.
The webinar will spotlight three key programs in various stages of development. CLD-201, which has received FDA clearance, is advancing toward clinical trials for solid tumors. Additionally, the company will discuss CLD-400, targeting metastatic and lung cancer, and CLD-101, aimed at treating high-grade gliomas.
Calidi's innovative approach utilizes allogeneic stem cells capable of carrying oncolytic viruses, potentially offering a groundbreaking method for cancer treatment. The technology aims to protect, amplify, and enhance virus efficacy while improving patient safety through a universal, off-the-shelf cell-based delivery platform.
The preclinical programs represent a dual approach that could potentially treat or even prevent metastatic disease, marking a significant advancement in cancer immunotherapy research. By leveraging stem cells as delivery mechanisms, Calidi is exploring novel strategies to empower the immune system in combating cancer.
Following the presentation, a live question-and-answer session will allow investors and stakeholders to gain deeper insights into the company's technological approach and future development strategies.
